The Innovation Agency and our fellow AHSNs are offering support to organisations responding to the NHS MedTech Funding Mandate policy.

The policy aims to accelerate the uptake of selected innovative medical devices, diagnostics and digital products. The guidance for 2021/22 is published here.


The technologies that will be supported by the policy in 2021/22 are:

PLG-F Triage Test (Placental Growth Factor – Quidel) 


Description: Point of care or laboratory blood test result within 20 minutes to measure elevation of one protein biomarker detectable before the onset of pre-eclampsia. 98% accuracy to rule out pre-eclampsia for 14 days.

Related clinical specialism: Women and children’s

Read more

PLGF Ratio Test (Placental Growth Factor – Roche) 


Description: Blood test to measure the ratio of two protein biomarkers detectable before the onset of pre-eclampsia. 99.3% accuracy to rule out pre-eclampsia for one week, preventing unnecessary monitoring, and helps detect other placental conditions.

Related clinical specialism: Women and children’s

Read more



Description: A standard coronary CT scan is uploaded to HeartFlow, which produces an FFRCT, and a 3D model of the coronary arteries. Reduces unnecessary invasive angiograms by specifically identifying site and degree of coronary artery block.

Related clinical specialism: Cardiology: for use in stable, recent onset chest pain and suspected angina.

Read more



Description: Patient-handheld medical device that enables self-administering discrete doses of non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of cluster headache. Reduces need for medication, increases self-management.

Related clinical specialism: Neurology

Read more



Description: Subcutaneous catheter stabilization device with small nickel feet placed just beneath the skin at the insertion site. Reduces need for adhesive dressings, cleaning time and dislodgement rates.

Related clinical specialism: IV access: safety device for PICC lines.

Read more



About the policy


In 2021/22 the policy will support devices, diagnostics or digital products that:

  • are effective: demonstrated through positive NICE guidance;
  • deliver material savings to the NHS: the benefits of the innovation are over £1 million over five years for the population of England;
  • are cost-saving in-year: NICE modelling demonstrates a net saving in the first 12 months of implementing the technology;
  • are affordable to the NHS: the budget impact should not exceed £20 million, in any of the first three years.

To minimise burden on the NHS at this time, it was agreed that for the first year of the policy only, technologies must have also been previously supported by the Innovation Technology Payment.

The AAC expects hospitals and commissioning organisations to comply with the policy guidance where appropriate. The Mandate directs the NHS to which MedTech innovations are effective and likely to give savings on investment. The NHS Standard Contract will require both commissioners and providers of NHS-funded services to comply, as relevant, with their obligations under, and any recommendations contained in, the MedTech Funding Mandate.

Once the policy becomes effective in April, the NHS Accelerated Access Collaborative (AAC) team will regularly review NICE guidance on medical technologies and diagnostics to identify medical devices, diagnostics and digital products which have been recommended by NICE and are likely to meet the MedTech Funding Mandate criteria in the following year, and highlight these to providers and commissioners.

All the latest from the Innovation Agency...